Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever
Date
2018Author
Korkmaz, Merve
Seyahi, Nurhan
Trabulus, Sinan
Kaya, Eda
Metadata
Show full item recordAbstract
Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.
Collections
- Makale [92796]